Introduction
============

Sepsis is a leading cause of death in critically ill patients despite improvements in antimicrobial therapy and supportive care \[[@B1]\]. The septic response is an extremely complex chain of events involving inflammatory and anti-inflammatory processes, hormonal and cellular reactions, and circulatory abnormalities \[[@B2],[@B3]\]. Early identification of patients at high risk of dying after intensive care unit (ICU) admission may help determine therapeutic interventions, such as changes in therapeutic protocols or further diagnostic procedures aiming at preventing shock and multiple organ failure with all their sequels that could have an impact on patients\' outcome \[[@B4]-[@B6]\]. Therefore, there is a need for a fast simple and cost-effective method to enhance risk stratification in septic patients.

Brian natriuretic peptide (BNP) and its inactive cleavage product N-terminal fragment (NT-proBNP) were secreted into the blood in response to atrial or ventricular wall stretch \[[@B7]\], or myocardial ischemia \[[@B8]\] by cardiomyocytes. The half-life of BNP is approximately 20 minutes, and that of NT-proBNP is 1-2 hours \[[@B9]\]. The term BNPs will be used to represent either BNP or NT-proBNP throughout the rest of the paper unless otherwise stated.

BNPs have been found to be useful markers in the diagnosis, management and prognosis of patients with congestive heart failure \[[@B10]\]. In addition, BNPs are powerful predictors of death and major adverse cardiovascular events in patients with stable coronary disease \[[@B11]\], acute coronary syndromes \[[@B12]\] and pulmonary embolism, \[[@B13]\] and those who undergo noncardiac surgery \[[@B14]\]. Several prospective studies have been performed to investigate the potential role of BNPs in predicting mortality in septic patients, but they had limited numbers of patients, used different cut-off points and involved different clinical endpoints. In the present study, we made a systematic review and meta-analysis to evaluate the correlation between elevated levels of BNPs and death in septic patients.

Materials and methods
=====================

This systematic review and meta-analysis was performed according to the guidelines of Meta-analysis of Observational Studies in Epidemiology \[[@B15]\].

Study outcome
-------------

The aim of this meta-analysis was to see whether elevated BNPs could predict all-cause mortality in adult patients with sepsis.

Search strategy and eligibility assessment
------------------------------------------

Pubmed, Embase and the Cochrane Central Register of Controlled Trials (up to February 18, 2011) were searched by using Exploded Medical Subject Headings and the appropriate corresponding keywords, \"Brain natriuretic peptide\", \"B-type natriuretic peptide\", \"BNP\", \"pro-brain natriuretic peptide\", \"amino terminal pro-brain natriuretic peptide\", \"amino terminal pro-BNP\", \"N-terminal pro B-type natriuretic peptide\", \"NT-proBNP\", \"natriuretic peptide\" AND \"sepsis\", \"septicemia\", \"septicaemia\", \"septic\". No language restrictions were applied. Additionally, the reference lists of the original studies and previous review articles were hand-searched to identify other potentially eligible studies.

Two authors independently determined the eligibility of all studies identified in initial research. Studies were included if they prospectively collected data on all-cause mortality in adult septic patients with either plasma BNP or NT-proBNP measurement. Studies where a 2 × 2 table of results could not be constructed were excluded. In case of disagreements, a third author was consulted. Agreement regarding study inclusion was assessed using the Cohen К statistic \[[@B16]\].

Data extraction and quality assessment
--------------------------------------

Two authors independently extracted the following descriptive data from all eligible studies: study design, sample size, patient population, inclusion/exclusion criteria, diagnostic criteria for sepsis, severe sepsis and septic shock, follow-up period, completeness of follow-up, outcome assessment, marker evaluated (i.e., BNP or NT-proBNP), assay manufacturer, the optimal cut-off point, timing of BNP measurement, and the proportion of patients with an elevated BNP measurement. If data needed clarification or were not presented in the publication, the original authors were contacted by E-mail. Extracted data were entered into Microsoft Office Excel 2007 and checked by the third author. Any disagreement was solved by discussion.

Given that the eligible studies were of a prognostic nature, methodological and reporting quality was assessed according to the Quality Assessment of Diagnostic Accuracy Studies checklist (see Additional file [1](#S1){ref-type="supplementary-material"}) \[[@B17]\].

Statistical analysis
--------------------

Results were analyzed using Review Manager 5.1 (Cochrane Collaboration, Oxford, UK) and Meta-Disc 1.4 \[[@B18]\] (Clinical Biostatistics, Ramon y Cajal Hospital, Madrid, Spain). As individual studies used different cut-off points for defining elevated BNPs, Spearman\'s correlation coefficient between sensitivity and specificity was calculated to detect the presence of a threshold effect, where variations in sensitivity and specificity were related to differences in the cut-off point used to define an elevated BNPs level \[[@B19]\]. If there was no evidence of a threshold effect, then summary estimates, including odds ratio (OR), sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio, were calculated using the random-effects model based on DerSimonian and Lair\'s meta-analytic statistical method \[[@B20]\]. In case a study provided multiple cut-off points for BNPs analysis, the point giving the maximum overall accuracy was chosen. In the case of analyses with empty cells, 0.5 was added to all cells to avoid computational errors. Publication bias was assessed by visually inspecting funnel plot. A p value of less than 0.05 was considered statistically significant.

Cochrane\'s Chi^2^test and I^2^test for heterogeneity were used to assess inter-study heterogeneity \[[@B21]\]. The Chi^2^test assesses whether observed differences in results are compatible with chance alone and the I^2^describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error. Statistically significant heterogeneity was considered present at Chi^2^*P*\< 0.10 and I^2^\> 50%. To explore the heterogeneity observed, sensitivity analyses were performed by sequential exclusion of each study. A prior subgroup analyses to explain significant heterogeneity were: 1) BNPs type (BNP versus NT-proBNP); and 2) blinding of BNPs measurement to the outcome (yes versus no). Single covariate random-effects meta-regression (inverse variance weights) was also used to explore sources of variation. Patient population (sepsis versus severe sepsis or septic shock), the underlying diseases (inclusion versus exclusion of preexisting conditions known to increase BNPs levels), optimal timing of BNPs measurement, and mortality were considered as variables.

Results
=======

Our initial search yielded 484 citations, of which 464 were eliminated for various reasons based on the title and abstract. The full texts of the remaining 20 articles were scrutinized for further evaluation. Twelve studies \[[@B22]-[@B33]\] fulfilled our eligibility criteria and were finally included (Figure [1](#F1){ref-type="fig"}). The Cohen statistic К for agreement on study inclusion was 0.90.

![**Flow-chart of study selection**.](cc11331-1){#F1}

Characteristics of included studies
-----------------------------------

The included studies were published from 2004 to 2011 and all were prospective cohort studies (Table [1](#T1){ref-type="table"}). Among them, seven studies \[[@B26]-[@B29],[@B31]-[@B33]\] were conducted in Europe, three \[[@B24],[@B25],[@B30]\] in Asia, one \[[@B22]\] in North America, and one \[[@B23]\] in Australasia. Two studies \[[@B22],[@B28]\] were multicenter studies and one study \[[@B23]\] reported both BNP and NT-proBNP. All studies but one \[[@B24]\] were published in English. The mean age of the patients varied between 55 and 69 years and the proportion of men ranged from 47 to 82%. The subject population varied across studies: three \[[@B22],[@B25],[@B26]\] included patients with sepsis, and nine \[[@B23],[@B24],[@B27]-[@B33]\] with severe sepsis or septic shock. The selected studies were performed in various departments, including emergency department, medical ICU, surgical ICU and general ICU. Nine studies \[[@B22],[@B24],[@B26],[@B27],[@B29]-[@B33]\] excluded patients with preexisting conditions known to increase BNPs levels. Follow-up periods differed across studies, including 28 days, ICU stay and hospital stay.

###### 

Characteristics of included studies

  Marker      Study                         Country     Setting                                              Population                                **NO**.   Male (%)   Age (year)         Outcome                         Mortality (%)
  ----------- ----------------------------- ----------- ---------------------------------------------------- ----------------------------------------- --------- ---------- ------------------ ------------------------------- ---------------
  NT-proBNP   Varpula 2007 \[[@B28]\]       Finland     24 ICUs                                              Severe sepsis or septic shock             254       69         59 ± 15            In-hospital mortality           26
              Mokart 2007 \[[@B29]\]        France      ICU                                                  Cancer patients developing septic shock   51        63         56 (50 - 68)^†^    ICU mortality                   51
              Roch 2005 \[[@B31]\]          France      General ICU                                          Septic shock                              39        82.1       63 ± 12            ICU mortality                   56
              Brueckmann 2005 \[[@B32]\]    Germany     Three departments in one hospital^‡^                 Severe sepsis                             57        74         55.0 ± 16.3        28-day mortality                28
              Sturgess 2010b\* \[[@B23]\]   Australia   ICU                                                  Septic shock                              21        61.9       65 ± 17            In-hospital mortality           29
  BNP         Perman 2011 \[[@B22]\]        USA         Emergency departments of 10 centers                  Clinical evidence of sepsis               825       49         53.5 ± 19.6        A composite of events ^**§**^   6.6
              Zhao 2009 \[[@B24]\]          China       Surgical ICU                                         Severe sepsis or septic shock             102       53.9       **─**              28-day mortality                38.2
              Chen 2009 \[[@B25]\]          China       Emergency department                                 Sepsis                                    327       60.6       69.5 ± 13.4        28-day mortality                37.3
              Yucel 2008 \[[@B26]\]         Turkey      General ICU                                          Sepsis                                    40        **─**      **─**              28-day mortality                50
              Post 2008 \[[@B27]\]          Germany     ICU                                                  Septic shock                              93        55         65(53 - 73.5)^†^   30-day mortality                40.9
              Ueda 2006 \[[@B30]\]          Japan       Department of Emergency and Critical Care Medicine   Septic shock                              22        77.3       62.5 ± 19.3        28-day mortality                54.5
              Charpentier 2004 \[[@B33]\]   France      Medical ICU                                          Severe sepsis or septic shock             34        47.1       56 ± 15.7          28-day mortality                29
              Sturgess 2010a\* \[[@B23]\]   Australia   ICU                                                  Septic shock                              21        61.9       65 ± 17            In-hospital mortality           29

BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide, ICU = intensive care unit. \*The study reported both BNP (Sturgess 2010a) and NT-proBNP (Sturgess 2010b). ^†^Median (25th - 75th percentiles). ^**¶**^Dash indicates that information was not provided. ^**§**^Events include in-hospital mortality, severe sepsis, or septic shock within 30 days following presentation. ^‡^Anesthesiology Department, Cardiosurgical Anesthesiology Department, and Internal Medicine Department.

BNPs measurements
-----------------

Among the included studies, BNP measurement was performed in eight \[[@B22]-[@B27],[@B30],[@B33]\] and NT-proBNP in five \[[@B23],[@B28],[@B29],[@B31],[@B32]\] (Table [2](#T2){ref-type="table"}). In the BNP studies, four \[[@B22],[@B23],[@B25],[@B27]\] used immunoﬂuorescence assay of Triage BNP test (Biosite Diagnostics, San Diego, CA), three \[[@B26],[@B30],[@B33]\] utilized immunoradiometric assay (Shionora-BNP), and one \[[@B24]\] did not report the method of BNP assay. In the NT-proBNP studies, four \[[@B23],[@B28],[@B29],[@B31]\] used an electrochemiluminescence immunoassay performed on a Roche analyzer (Roche Diagnostics), and one study \[[@B32]\] utilized an enzyme immunoassay (Biozol). Among the included studies, receiver operating characteristic (ROC) curve was performed to retrospectively determine the optimal cut-off point with regard to 28-day mortality in seven studies \[[@B24]-[@B27],[@B30],[@B32],[@B33]\], ICU mortality in two studies \[[@B29],[@B31]\], in-hospital mortality in two study \[[@B23],[@B28]\], and a composite outcome of in-hospital mortality, severe sepsis, or septic shock in one study \[[@B22]\]. Normal BNPs levels were defined as levels beneath or equal to the optimal cut-off points. The optimal cut-off points varied greatly across studies, from 32.1 pg/ml to 681.4 pg/ml for BNP, and from 400 pg/ml to 13,600 pg/ml for NT-proBNP. There were wide variations about the optimal timing of BNP measurement (six studies \[[@B22],[@B24]-[@B26],[@B28],[@B31]\]: the day on admission; five studies \[[@B23],[@B29],[@B30],[@B32],[@B33]\]: day 2 after admission; one study \[[@B27]\]: day 5 after admission).

###### 

NT-proBNP and BNP measurements

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker      Study                         Assay^†^                             Optimal Timing                    Cut-off Point\   Sensitivity/Specificity   AUC^¶^   Proportion of Elevated BNPs (%)
                                                                                                                   (pg/ml)                                             
  ----------- ----------------------------- ------------------------------------ --------------------------------- ---------------- ------------------------- -------- ---------------------------------
  NT-proBNP   Varpula 2007 \[[@B28]\]       Roche, Elecsys 2010 analyzer         On admission                      7090             58/66                     0.631    40.6

              Mokart 2007 \[[@B29]\]        Roche, Elecsys 2010 analyzer         Day 2 after admission             6624             86/77                     0.87     54.9

              Roch 2005 \[[@B31]\]          Roche, Elecsys 2010 analyzer         Within 24 hours after admission   13600            73/83                     0.8      48.7

              Brueckmann 2005 \[[@B32]\]    Enzyme immunoassay (Biozol)          Day 2 after admission             11900            50/90                     0.68     21.1

              Sturgess 2010b\* \[[@B23]\]   Roche, Elecsys 2010 analyzer         Within 72 hours after admission   400              83/40                     0.67     66.7

  BNP         Perman 2011 \[[@B22]\]        Biosite Diagnostics, Triage          On admission                      49               63/69                     0.69     47.6

              Zhao 2009 \[[@B24]\]          Immunofluorescence assay^**‡**^      24 hours after admission          681.4            91.4/80.3                 0.915    47.1

              Chen 2009 \[[@B25]\]          Biosite Diagnostics, Triage          Within 24 hours after admission   113              86/55                     0.737    32.1

              Yucel 2008 \[[@B26]\]         Immunoradiometric assay, Shionoria   On admission                      32.1             100/95                    0.99     52.5

              Post 2008 \[[@B27]\]          Biosite Diagnostics, Triage          Day 5 after admission             121              76.3/52.7                 0.648    59.1

              Ueda 2006 \[[@B30]\]          Immunoradiometric assay, Shionoria   Day 2 after admission             650              92/80                     0.85     59.1

              Charpentier 2004 \[[@B33]\]   Immunoradiometric assay, Shionoria   Day 2 after admission             190              70/67                     0.66     44.1

              Sturgess 2010a\* \[[@B23]\]   Biosite Diagnostics, Triage          Within 72 hours after admission   254              83/60                     0.76     52.4
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide. \*The study reported both BNP (Sturgess 2010a) and NT-proBNP (Sturgess 2010b). ^**†**^Manufacture and kind of assay. ^**‡**^The manufacture was not reported. ¶ AUC indicates the area under the receiver operating characteristic curve.

Study quality and publication bias
----------------------------------

All the twelve included studies fulfilled the requirements of a representative spectrum of patients, and clearly described selection criteria, outcome verification in the whole cohort, equal outcome evaluation regardless of the BNPs results, sufficient description of BNPs measurement for replication and availability of clinical data. Four studies \[[@B22],[@B28],[@B30],[@B33]\] stated that the BNPs results were interpreted without knowledge of outcome assessment. Because the target condition was mortality, outcome assessment was unlikely to be influenced by knowledge of the BNPs results. No patient was lost to follow-up.

Regarding the predictive value of elevated BNPs for mortality, there was no evidence of significant publication bias by inspection of the funnel plot (Figure [2](#F2){ref-type="fig"}).

![**Funnel plot for the predictive value of elevated BNP or NT-proBNP for mortality in patients with sepsis**. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.](cc11331-2){#F2}

Predictive value of BNPs on all-cause mortality
-----------------------------------------------

Overall, 349 (37.6%) of the 929 patients with elevated BNPs died *vs*90 (9.4%) of the 957 patients with normal BNPs. Spearman\'s correlation coefficient between sensitivity and specificity was -0.132 (*P*= 0.667), suggesting no evidence of a threshold effect. Therefore, pooled estimates were calculated. Elevated BNPs were associated with a significantly increased risk of all-cause mortality (OR 8.65, 95% confidence interval (CI) 4.94 to 15.13, *P*\< 0.00001, Figure [3](#F3){ref-type="fig"}) with significant heterogeneity (I^2^= 64%, *P*= 0.001). The pooled sensitivity and specificity were 79% (95% CI 75 to 83, Figure [4](#F4){ref-type="fig"}) and 60% (95% CI 57 to 62, Figure [5](#F5){ref-type="fig"}), respectively. The summary positive and negative likelihood ratios were 2.27 (95% CI 1.83 to 2.81, Figure [6](#F6){ref-type="fig"}) and 0.32 (95% CI 0.22 to 0.46, Figure [7](#F7){ref-type="fig"}), respectively.

![**Summary of odds ratio of mortality in septic patients with elevated BNP or NT-proBNP**. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.](cc11331-3){#F3}

![**Summary of sensitivity of elevated BNP or NT-proBNP in predicting mortality**. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.](cc11331-4){#F4}

![**Summary of specificity of elevated BNP or NT-proBNP in predicting mortality**. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.](cc11331-5){#F5}

![**Summary of the positive likelihood ratio of elevated BNP or NT-proBNP in predicting mortality**. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.](cc11331-6){#F6}

![**Summary of the negative likelihood ratio of elevated BNP or NT-proBNP in predicting mortality**. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.](cc11331-7){#F7}

The prior sensitivity analysis suggested that the heterogeneity was accounted for by two studies which had the minimum \[[@B28]\] and maximum \[[@B26]\] areas under the ROC curve. With the two studies excluded, the pooled OR was not significantly altered (OR 8.67, 95% CI 5.46 to 13.77, *P*\< 0.00001) with no significant heterogeneity (I^2^= 33%, *P*= 0.13). Subgroup analyses suggested that the association between elevated BNPs and increased risk of all-cause mortality was consistent for BNP (OR 10.44, 95% CI 4.99 to 21.58, *P*\< 0.00001; I^2^= 64%) \[[@B22]-[@B27],[@B30],[@B33]\] and NT-proBNP (OR 6.62, 95% CI 2.68 to 16.34, *P*\< 0.0001; I^2^= 57%) \[[@B23],[@B28],[@B29],[@B31],[@B32]\], as well as blinding (OR 3.83, 95% CI 2.52 to 5.82, *P*\< 0.00001; I^2^= 0%) \[[@B22],[@B28],[@B30],[@B33]\] and no blinding (OR 14.24, 95% CI 6.56 to 30.93, *P*\< 0.00001; I^2^= 63%) \[[@B23]-[@B27],[@B29],[@B31],[@B32]\] of BNPs measurement to the outcome. According to our priori hypothesis, meta-regression analyses showed that patient population (*P*= 0.76), the underlying diseases (*P*= 0.12), optimal timing of BNPs measurement (*P*= 0.89), and mortality (*P*= 0.10) did not explain the demonstrated heterogeneity, respectively.

Discussion
==========

The present meta-analysis showed that elevated BNPs were associated with a significantly increased risk of mortality in patients with sepsis. The finding is consistent for both BNP and NT-proBNP. As such, measurement of BNPs may be a simple method of risk stratification in septic patients.

BNPs elevation in patients with sepsis can be considerably high, even though cardiac depression is not obvious. A retrospective study \[[@B34]\] suggested that BNPs level in septic patients with preserved systolic left ventricular function could be as high as that in patients admitted to the hospital with congestive heart failure because of severely impaired systolic left ventricular function. Aside from neurohormonal activation, several mechanisms are likely to account for increased BNPs levels in sepsis, including sepsis-induced biventricular dilatation \[[@B35]\], the stimulation of lipopolysaccharide \[[@B36]\] or proinflammatory cytokines \[[@B37],[@B38]\], volume resuscitation \[[@B39]\] and sepsis-associated acute lung injury or acute respiratory distress syndrome \[[@B40]\]. Accordingly, elevated BNPs level in the presence of sepsis does not essentially mean cardiac dysfunction due to low specificity, while normal BNPs level could be used to rule out the need for further cardiac investigation, unless there are other clinical grounds that strongly suspect a significant cardiac disorder.

Clinical severity scores such as acute physiology and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores have been validated for mortality risk stratification, but are unwieldy and tend to be used more for audit and research than clinical decision making in sepsis. A rapidly available biochemical test that provides similar or better prognostic information could therefore be useful, e.g. to help discussions about prognosis with patients\' relatives and decisions regarding earlier interventions. Several studies \[[@B25],[@B41],[@B42]\] showed that BNPs level was related to APACHE II and SOFA scores. In the present meta-analysis, two \[[@B25],[@B27]\] of the included studies directly compared the prognostic value of BNPs measurement *vs*clinical severity scores and both suggested a better prognostic value of elevated BNPs in predicting mortality. Chen et al \[[@B25]\] reported a greater area under the ROC curve for the plasma BNP level than for APACHE Ⅱ score (0.737 *vs*0.664). Post et al \[[@B27]\] reported that regarding predicting 30-day mortality, the area under the ROC curve was greater for BNP than that for APACHE Ⅱ score and SOFA score (0.648 *vs*0.494 and 0.493, respectively). Considering the low sensitivity and high specificity of clinical severity scores, they can be combined with BNPs for aggregate analysis on the septic prognosis. What additional value of BNP brings to severity scores on sepsis risk stratification remains to be determined in further studies.

As a risk stratification tool, BNPs measurement is simple, inexpensive, reproducible, non-invasive, and widely available. These attributes make it highly suitable for serial testing to monitoring outcome risk over time, which may be superior to a single value of BNPs assessed on admission, because dynamic changes in BNPs concentration may reflect the development of sepsis. Furthermore, rather than necessarily dichotomizing risk as high or low, BNPs express risk as a continuum and this may be advantageous.

To date, several biomarkers have been identified to have some prognostic value in the field of sepsis. According to a prospective multicenter observational study \[[@B43]\] procalcitonin \> 0.85 ng/ml was associated with an increased risk of death in a Cox regression analysis (hazard ratio 2.31, 95% CI 1.32-4.05, P = 0.003). In addition, both elevated cardiac troponin-T \[[@B44]\] and -I \[[@B45]\] were reported to be associated with higher mortality in septic patients. In the present study, pooled sensitivity and specificity of elevated BNPs for predicting mortality in septic patients were 79% and 60%, respectively. So far, none of the proposed prognostic markers had sufficient (more than 90%) sensitivity and specificity to predict which patients were at greater risk of dying due to sepsis \[[@B46]\]. Accordingly, a BNPs measurement may provide a better prognostic value in combination with other biomarkers, each mirroring different pathophysiological aspects. Further study was warranted to verify this hypothesis and evaluate the cost-effectiveness in sepsis.

In the past decade, several fully automated, rapid assays for determination of BNPs have become commercially available, including both high-throughput automated platforms and point of care tests. Although these existing BNPs assays correlate closely, BNPs assays are not currently analytical equivalent due to the lack of assay standardization \[[@B47]\]. Recently, a multicenter study conducted in 90 Italian laboratories demonstrated that there were significant differences in analytical characteristics and measured values among the most popular commercial methods for BNP and NT-proBNP \[[@B48]\]. Therefore, clinicians should be very careful when comparing results obtained by laboratories that use different methods.

An important concern of using BNPs in septic patients is the impact of renal insufficiency on these tests. Acute renal insufficiency occurs in 11 - 16% of critically ill patients who presented with sepsis \[[@B49],[@B50]\]. A study by Goei et al \[[@B51]\] suggested that NT-proBNP had more favorable discriminative value in patients with a glomerular filtration rate more than 90 mL/min/1.73 m^2^, while it lost its prognostic value in patients with a glomerular filtration rate less than 30 mL/min/1.73 m^2^. No guidance on how BNPs values are adjusted for renal dysfunction is available today. Given the high prevalence and the impact of renal impairment on the BNPs values, it is preferable to adopt different cut-offs stratified by renal function in patients with sepsis.

There were several limitations in the present study. First, marked heterogeneity existed across the included studies in terms of population characteristics, BNPs assays, optimal cut-off point, follow-up period and definitions of endpoints. However, all the individual ORs favored the prognostic value of elevated BNPs in predicting mortality, indicating that the heterogeneity was entirely quantitative. Although there was uncertainty regarding the strength of the association, current evidence suggested that there was a significant correlation between an elevated BNPs level and an increased risk of mortality in septic patients. Second, the optimal timing of BNPs measurement varied across the studies, including the day on admission, and day 2 and day 5 after admission. It can be partly accounted for by the difficulty in determining the time of onset of sepsis and, hence, the time of patient recruitment. Third, it should be noted that the pooled estimates reflected unadjusted associations between BNPs and all-cause mortality. Five \[[@B22],[@B25],[@B27],[@B29],[@B31]\] of the included studies provided adjusted ORs accounting for confounders. Pooled analysis of the adjusted ORs also suggested that elevated BNPs were correlated with a significantly increased risk of mortality in septic patients (random-effects model, OR 1.87, 95% CI 1.30 to 2.69, *P*= 0.001). Because the ORs in the five studies were adjusted by different confounders with different regression models and the data reported on adjusted ORs were limited, we thus adopted unadjusted mortality data for pooled analyses in the present study. Finally, we could not determine the ideal cutoff points for BNP and NT-proBNP tests because we did not have the raw data to map out ROC curves. To determine whether there is a single threshold or a few important BNP or NT-proBNP thresholds (e.g., age dependent), further evaluation in prespecified groups of larger numbers of patients is needed.

Conclusions
===========

This systematic review and meta-analysis suggests that an elevated BNP or NT-proBNP level may prove to be a powerful predictor of mortality in patients with sepsis. This test appears to represent a rapid and relatively inexpensive method to enhance mortality prediction in sepsis. Future larger and more adequately powered prospective studies are warranted to clarify the assay standardization, the optimal cut-off, and the prognostic value of BNPs in conjunction with other biomarkers.

Key messages
============

• The literature shows that an elevated BNP or NT-proBNP level is a powerful predictor of mortality in patients with sepsis.

• This test appears to represent a rapid and relatively inexpensive method to enhance mortality prediction in sepsis.

• Larger adequately powered prospective studies are warranted to clarify the assay standardization, the optimal cut-off, and the prognostic value of BNPs in conjunction with other biomarkers in future.
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